Benzinga | Oct 11, 2021 10:30AM EDT

NYMOX Provides Current Update

Nymox Pharmaceutical Corporation (NASDAQ:NYMX) (the "Company") is pleased to report today a one-month update to shareholders as a follow-up to the September communication. The Company reinforces that its completion tasks for the important Fexapotide filing have advanced as anticipated and that substantial progress has ensued.



Company CEO Paul Averback stated, "We are happy to follow-up today and tell our shareholders that the main delayed vendor documentation that was incomplete has been accomplished. We are now certain to have our full documentation for those materials completed. There remain some standard quality control steps that are typically involved. Our next follow-up is expected to provide a more exact forward date for filing as soon as it is in our hands very soon in this quarter. We emphasize again that it is fully in the best interests of our shareholders that management concerns itself with required quality regulations and stays focused on doing things properly, regardless of the recent very minor adjustments to the timeline, which are beyond our control."

The Company also announced today that it will be participating in several investor conferences and meetings in the upcoming months.

About Nymox Pharmaceutical Corporation

Nymox Pharmaceutical Corporation specializes in the research and development of therapeutics and diagnostics, with a particular emphasis on products targeted for the unmet needs of the rapidly aging male population in developed economies. The Company's lead drug candidate for benign prostatic hyperplasia (BPH), Fexapotide Triflutate (FT), has completed Phase 3 development in more than 70 clinical centers in the United States, involving more than 1700 patients during the entire clinical development program. Currently, the Company will soon be filing for approval in major economies around the world, including the United States and Europe.

For more information please contact info@nymox.com or 800-936-9669.